Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | CPB1 | P15086 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2851466 | 1.00 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2HSD11B1JAK2 | |
| SCHEMBL28702705 | 0.93 | HSD11B1 (0.48) | NPC1RAB9ASMN1; SMN2HSD11B1JAK2 | |
| SCHEMBL16667924 | 0.93 | HSD11B1 (0.48) | NPC1RAB9ASMN1; SMN2HSD11B1JAK2 | |
| SCHEMBL5435529 | 0.93 | HSD11B1 (0.48) | NPC1RAB9ASMN1; SMN2HSD11B1JAK2 | |
| SCHEMBL2845315 | 0.93 | HSD11B1 (0.48) | NPC1RAB9ASMN1; SMN2HSD11B1JAK2 | |
| SCHEMBL2845311 | 0.93 | HSD11B1 (0.48) | NPC1RAB9ASMN1; SMN2HSD11B1JAK2 | |
| SCHEMBL14911483 | 0.92 | PDE4B (0.56) | NPC1RAB9ASMN1; SMN2HSD11B1JAK2 | |
| SCHEMBL16164661 | 0.92 | PDE4B (0.56) | NPC1RAB9ASMN1; SMN2HSD11B1JAK2 | |
| SCHEMBL29492127 | 0.91 | HSD11B1 (0.50) | NPC1RAB9ASMN1; SMN2HSD11B1JAK2 | |
| SCHEMBL20479857 | 0.90 | PDE4B (0.49) | NPC1RAB9ASMN1; SMN2STSCPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2226322-B1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8927588-B2 | Imidazole carbonyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-01-06 | — | — | US | disclosed |
| US-20140073622-A1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8536197-B2 | Imidazole carbonyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-17 | — | — | US | disclosed |
| US-20100311966-A1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2226322-A1 | IMIDAZOLE CARBONYL COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311966-A1 | IMIDAZOLE CARBONYL COMPOUND | TOP1, TOP2B, TOP2A | NPC1 1573/4885RAB9A 2042/4885SMN1; SMN2 4001/4885 |
| US-20140073622-A1 | IMIDAZOLE CARBONYL COMPOUND | TOP1, TOP2B, TOP2A | NPC1 630/4885RAB9A 2487/4885SMN1; SMN2 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.